Table 3.
Maintenance dose of warfarin by GGCX SNPs, stratified by race
| SNP | Major allele (A) | Minor allele (B) | AA (n) | AB (n) | BB (n) | AA Median dose (min−max) | AB Median dose (min−max) | BB Median dose (min−max) | P value* | Partial R2* |
|---|---|---|---|---|---|---|---|---|---|---|
| African American | ||||||||||
| rs7568458 | A | T | 10 | 11 | 1 | 41.25 (10.00–67.50) | 45.00 (25.00–80.00) | 35.00 | 0.58 | 0.02 |
| rs6751560 | G | A | 18 | 4 | 0 | 40.00 (10.00–80.00) | 43.75 (26.25–52.50) | – | 0.96 | <0.001 |
| rs17026452 | G | C | 18 | 3 | 1 | 40.00 (10.00–80.00) | 37.50 (26.25–50.00) | 52.50 | 0.78 | 0.005 |
| rs699664 | C | T | 2 | 10 | 10 | 48.75 (35.00–62.50) | 40.00 (25.00–80.00) | 41.25 (10.00–67.50) | 0.44 | 0.04 |
| rs2592551 | G | A | 5 | 12 | 5 | 35.00 (26.25–62.50) | 45.00 (25.00–80.00) | 32.50 (10.00–67.50) | 0.55 | 0.02 |
| rs10179904 | G | A | 20 | 2 | 0 | 41.25 (10.00–80.00) | 36.25 (27.50–45.00) | – | 0.71 | 0.01 |
| rs11676382 | C | G | 22 | 0 | 0 | 41.25 (10.00–80.00) | – | – | – | – |
| rs17026447 | A | C | 20 | 1 | 0 | 41.25 (10.00–80.00) | 52.50 | – | – | – |
| Caucasian | ||||||||||
| rs7568458 | A | T | 6 | 18 | 12 | 32.75 (20.00–55.00) | 36.75 (17.50–80.00) | 40.63 (17.50–95.00) | 0.93 | <0.001 |
| rs6751560 | G | A | 33 | 3 | 0 | 37.50 (17.50–95.00) | 42.50 (23.00–50.00) | – | – | – |
| rs17026452 | G | C | 30 | 4 | 1 | 38.75 (17.50–95.00) | 28.75 (23.00–42.50) | 50.00 | 0.38 | 0.02 |
| rs699664 | C | T | 12 | 22 | 2 | 40.63 (17.50–95.00) | 36.75 (17.50–80.00) | 36.25 (22.50–50.00) | 0.84 | <0.001 |
| rs2592551 | G | A | 15 | 20 | 1 | 40.00 (17.50–95.00) | 38.75 (17.50–80.00) | 22.50 | 0.64 | 0.005 |
| rs10179904 | G | A | 33 | 3 | 0 | 37.50 (17.50–95.00) | 42.50 (20.00–55.00) | – | – | – |
| rs11676382 | C | G | 32 | 4 | 0 | 36.75 (17.50–95.00) | 41.63 (27.50–42.50) | – | 0.84 | <0.001 |
| rs17026447 | A | C | 31 | 5 | 0 | 37.50 (17.50–95.00) | 42.50 (27.50–55.00) | – | 0.31 | 0.02 |
*
The relationship between each SNP and log-transformed maintenance dose was adjusted for the VKORC1 1173C>T and CYP2C9*2 and *3 variants.